论文部分内容阅读
目的:探讨螺内酯对无症状左室收缩功能障碍患者心室重构的影响。方法:入选我院2007-12-2009-06门诊及住院无症状左室收缩功能障碍[左室射血分数(LVEF)<40%,左室舒张末期容积指数(LVEDVI)>75ml/m2,纽约心脏病协会心功能分级Ⅰ级]患者63例,在常规治疗的基础上随机分为螺内酯干预组32例(螺内酯40mg/d),对照组31例,所有患者在入选前及药物应用6个月后行超声心动图检查评估LVEDVI、左室收缩末期容积指数(LVESVI)、左室质量指数(LVMI)和LVEF的变化。结果:治疗6个月后,2组LVEDVI、LVES-VI、LVMI和LVEF均较治疗前有明显改善,且差异有统计学意义(均P<0.05),螺内酯组改善更为显著(均P<0.05)。结论:在常规治疗的基础上加用螺内酯治疗可进一步改善无症状左室收缩功能障碍患者的心室重构。
Objective: To investigate the effect of spironolactone on ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction. METHODS: In our hospital 2007-12-2009-06 Outpatient and inpatient asymptomatic left ventricular systolic dysfunction [LVEF <40%, LVEDVI> 75ml / m2, New York Sixty-three patients were divided into spironolactone-treated group (spironolactone 40mg / d) and control group (n = 31). All patients were enrolled before and 6 months Echocardiography was performed to assess changes in LVEDVI, LVESSVI, LVMI, and LVEF. Results: Six months after treatment, LVEDVI, LVES-VI, LVMI and LVEF were significantly improved in both groups (all P <0.05) and spironolactone group (all P < 0.05). Conclusion: Spironolactone can further improve ventricular remodeling in patients with asymptomatic LV systolic dysfunction based on routine treatment.